Better supplier management doesn't need to wait for the Operations Excellence program to mature in production. Many of the
above identified improvements can begin in parallel to production-related improvements.
However, companies need to face reality: The biopharm industry will not likely reach the production volumes of small molecule
producers or companies in other industries for years to come. Until better leverage is achieved, your company will need to
put in extra effort and management to minimize supplier risk to quality and delivery.
The latest East Coast consortium meeting was held August 22 at Human Genome Sciences in Rockville, MD. The meeting was well
attended and focused on the challenges of moving a new plant from qualification to commercial development. The session included
a tour of the new large scale facility. The next European Consortium is scheduled for September 26 at Avecia in the UK. Go
http://www.tefen.com/bio for information on past and future meetings.
Marc Puich is a partner at Tefen, Ltd., 1065 E. Hillsdale Blvd., Suite 421, Foster City, CA, 94404; Tel 650.357.1120 x117, Fax 650.372.1350,